<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00831025</url>
  </required_header>
  <id_info>
    <org_study_id>6018-PG-PSC-148</org_study_id>
    <secondary_id>2006-005727-41</secondary_id>
    <nct_id>NCT00831025</nct_id>
  </id_info>
  <brief_title>Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Olea Europaea Pollen</brief_title>
  <acronym>OLEA</acronym>
  <official_title>Multicenter, Randomised, Double-blind Placebo-controlled, Subcutaneous Immunotherapy Clinical Trial With Depigmented and Polymerized Allergen Extract of Olea Europaea Pollen in Patients With Hypersensitivity to Olea Pollen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Leti, S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios Leti, S.L.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this trial is to assess the clinical efficacy of a modified allergen extract
      of Olea europaea pollen in the treatment of patients affected by allergic
      rhinitis/rhinoconjunctivitis (with or without episodic asthma) induced by hypersensitivity to
      olea europaea pollen, evaluating the Score regarding Symptoms and consumption of the
      medication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Immunotherapy is a specific treatment for allergic diseases. Unlike conventional
      pharmacological treatment, immunotherapy is the only treatment that could modify the natural
      course of allergic disease. This is a prospective double-blind placebo-controlled study with
      two arms of treatment: placebo and active.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptoms and medication score</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose-response skin prick-test</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication score</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rhinoconjunctivitis quality of life questionnaire</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scales (VAS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serology</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms score</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exhaled nitric oxide</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">158</enrollment>
  <condition>Rhinitis or Rhinoconjunctivitis With or Without Asthma Induced by Hypersensitivity to Olea Europea Pollen</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Depigmented and polymerized allergen extract of Olea europaea pollen for subcutaneous injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for subcutaneous injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Immunotherapy with modified extract of Olea europaea pollen</intervention_name>
    <description>Subcutaneous immunotherapy with modified extract of Olea europaea. A subcutaneous monthly treatment.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for subcutaneous monthly administration</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prior to study specific examinations the patient and if applicable both legal
             guardians has to give his/her written informed consent

          -  Patients of both gender aged from 18 and 55 years

          -  Patient`s perception of disease activity of at least 30 mm on a 100 mm visual analogue
             scale (VAS)

          -  FEV1 greater or equal than 80% of the expected value, and if not, improvement of FEV1
             greater than 12% after bronchodilation

          -  Patients have to suffer from allergic complaints (rhinitis and/or rhinoconjunctivitis
             with or without mild intermittent allergic asthma) caused by clinical sensitization
             against Olea europaea pollen. The IgE mediated sensitization has to be verified by:

          -  Suggestive medical history

          -  Specific IgE against Olea europaea pollen CAP RAST ≥0.7Ku/l

          -  Positive skin prick test (SPT) to grass Olea pollen resulting in a wheal diameter of
             at least 3 mm.

        Exclusion Criteria

          -  History of significant clinical manifestations of allergy as a result of sensitization
             against weed pollen allergens and perennial (e.g. house dust mite.

          -  Participation in an immunotherapy with comparable extracts within the last five years.

          -  Treatment with β-blocker

          -  Any disease which prohibits the use of adrenaline (e.g. hyperthyroidism)

          -  Cardiovascular insufficiency or any severe or unstable pulmonary, or endocrine
             disease; clinically significant renal or hepatic disease or dysfunction; hematologic
             disorder; any other clinically significant medical condition that could increase the
             risk to the study participant

          -  Immunopathological diseases

          -  Patients who are expected to be non-compliant and/or not co-operative

          -  Women, where pregnancy is defined as the state of a female after conception and until
             the termination of gestation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro Guardia, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Hospital El Tomillar</name>
      <address>
        <city>Dos Hermanas</city>
        <state>Sevilla</state>
        <zip>41700</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Cecilio</name>
      <address>
        <city>Granada</city>
        <zip>18012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaén</name>
      <address>
        <city>Jaén</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Santa Isabel</name>
      <address>
        <city>Sevilla</city>
        <zip>41018</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2009</study_first_submitted>
  <study_first_submitted_qc>January 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2009</study_first_posted>
  <last_update_submitted>February 21, 2018</last_update_submitted>
  <last_update_submitted_qc>February 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Allergoid</keyword>
  <keyword>Depigmented</keyword>
  <keyword>Polymerized</keyword>
  <keyword>Allergen-extract</keyword>
  <keyword>Rhinoconjunctivitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Conjunctivitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

